Shares of Omnicell, Inc. (NASDAQ:OMCL – Get Free Report) have been assigned a consensus recommendation of “Hold” from the seven analysts that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $41.33.
A number of equities research analysts have recently commented on the stock. Barclays raised shares of Omnicell from an “underweight” rating to an “equal weight” rating and raised their price objective for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. Benchmark restated a “buy” rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. Bank of America lifted their price objective on shares of Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Wells Fargo & Company increased their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. lifted their price target on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd.
Check Out Our Latest Analysis on Omnicell
Institutional Trading of Omnicell
Omnicell Trading Down 1.5 %
Shares of Omnicell stock opened at $40.47 on Tuesday. Omnicell has a 1 year low of $25.12 and a 1 year high of $45.84. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22. The stock has a market cap of $1.86 billion, a PE ratio of -87.98, a price-to-earnings-growth ratio of 47.11 and a beta of 0.83. The firm has a fifty day moving average price of $43.22 and a 200 day moving average price of $34.42.
Omnicell (NASDAQ:OMCL – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.37. The business had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The company’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 EPS. Equities research analysts predict that Omnicell will post 0.64 earnings per share for the current year.
Omnicell Company Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Stories
- Five stocks we like better than Omnicell
- What Are Growth Stocks and Investing in Them
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- CD Calculator: Certificate of Deposit Calculator
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- How to Invest in Biotech Stocks
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.